Who are SSR591813L (dianicline)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROAMPHETAMINE, Atomoxetine (Strattera), VenlafaxineXR, venlafaxine (Effexor), Venlafaxine XR, desvenlafaxine succinate sustained release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ssr591813l-dianicline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

SSR591813L (dianicline) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SSR591813L (dianicline) (SSR591813L (dianicline)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: norepinephrine reuptake inhibitor. Area: Central Nervous System.

phase 3 norepinephrine reuptake inhibitor norepinephrine transporter Central Nervous System Small molecule Live · refreshed every 30 min

Target snapshot

SSR591813L (dianicline) (SSR591813L (dianicline)) — Sanofi. SSR591813L (dianicline) is a norepinephrine reuptake inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SSR591813L (dianicline) TARGET	SSR591813L (dianicline)	Sanofi	phase 3	norepinephrine reuptake inhibitor	norepinephrine transporter
DEXTROAMPHETAMINE	DEXTROAMPHETAMINE		marketed	Central nervous system stimulant	Dopamine transporter (DAT), Norepinephrine transporter (NET)	1955-01-01
Atomoxetine (Strattera)	Atomoxetine (Strattera)	University of Pittsburgh	marketed	Norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
VenlafaxineXR	VenlafaxineXR	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
venlafaxine (Effexor)	venlafaxine (Effexor)	National Institute of Mental Health (NIMH)	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT, weak)
Venlafaxine XR	Venlafaxine XR	Ministry of Health & Welfare, Korea	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
desvenlafaxine succinate sustained release	desvenlafaxine succinate sustained release	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-24 — DEXTROAMPHETAMINE · 9456993 · Formulation · US
2033-10-24 — DEXTROAMPHETAMINE · 9474722 · Formulation · US
2042-01-06 — DEXTROAMPHETAMINE · 11559501 · Formulation · US

Sponsor landscape (norepinephrine reuptake inhibitor class)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Kwang-Ha Yoo · 1 drug in this class
Sanofi · 1 drug in this class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SSR591813L (dianicline) — Competitive Intelligence Brief. https://druglandscape.com/ci/ssr591813l-dianicline. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab